{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:05:28Z","timestamp":1775066728914,"version":"3.50.1"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Although antifungal prophylaxis is frequently administered to patients with acute myeloid leukemia (AML) during remission-induction chemotherapy (RIC), its impact on reducing invasive fungal infections (IFIs) outside clinical trials is rarely reported. We performed a retrospective observational study to identify risk factors for development of IFIs (definite or probable, using revised European Organization for Research and Treatment of Cancer [EORTC] criteria) and all-cause mortality in a cohort of 152 AML patients receiving RIC (2009 to 2011). We also compared rates of IFI and mortality in patients who received echinocandin versus anti-\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus<\/jats:named-content>\n            azole (voriconazole or posaconazole) prophylaxis during the first 120 days of RIC. In multivariate analysis, clofarabine-based RIC (hazard ratio [HR], 3.5; 95% confidence interval [CI], 1.5 to 8.3;\n            <jats:italic>P<\/jats:italic>\n            = 0.004) and echinocandin prophylaxis (HR, 4.6; 95% CI, 1.8 to 11.9;\n            <jats:italic>P<\/jats:italic>\n            = 0.002) were independently associated with higher rates of IFI rates during RIC. Subsequent analysis failed to identify any malignancy- or chemotherapy-related covariates linked to echinocandin prophylaxis that accounted for the higher rates of breakthrough IFI. Although the possibility of other confounding variables cannot be excluded, our findings suggest that echinocandin-based prophylaxis during RIC for AML may be associated with a higher risk of breakthrough IFI.\n          <\/jats:p>","DOI":"10.1128\/aac.01527-13","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T04:42:09Z","timestamp":1393908129000},"page":"2775-2780","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia"],"prefix":"10.1128","volume":"58","author":[{"given":"Marisa Z. R.","family":"Gomes","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USA"},{"name":"Nosocomial Infection Research Laboratory, Instituto Oswaldo Cruz, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Mulanovich","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell E.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051995"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks189"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08650.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.10.009"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11665"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0783-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9743"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3294"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27429"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q295"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712461666"},{"key":"e_1_3_3_15_2","unstructured":"UK Medicines and Healthcare Products Regulatory Agency (MHRA). 2011 (updated 12 March 2013). Summary of product characteristics (Evoltra 1mg\/ml concentrate for solution for infusion). http:\/\/www.medicines.org.uk\/EMC\/medicine\/18023\/SPC\/Evoltra+1mg+ml+concentrate+for+solution+for+infusion\/. Accessed 17 November 2013."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181ff7e10"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0247"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.739-745.2002"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/429921"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22246"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01527-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01527-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:40:09Z","timestamp":1645483209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01527-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1128\/AAC.01527-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01527-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"2013-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}